SPATA6L

Across TCGA pan-cancer cohorts, SPATA6L Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SPATA6L data layer compared with 23 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher SPATA6L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SPATA6L expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUSC, BRCA, and LIHC are the cancer types where SPATA6L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.270	0.680	<.001	48	view →
BRCA	OS	Median	III,IV	0.106	0.906	<.001	34	view →
LIHC	OS	Median	All	0.144	0.688	.013	9	view →
UCEC	DFS	Median	II,III,IV	0.906	0.440	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SPATA6L–LUSC (OS)

Open the LUSC breakdown →